Literature DB >> 12610658

Evidence that the N-methyl-D-aspartate subunit 1 receptor gene (GRIN1) confers susceptibility to bipolar disorder.

E Mundo1, S Tharmalingham, M Neves-Pereira, E J Dalton, F Macciardi, S V Parikh, A Bolonna, R W Kerwin, M J Arranz, A J Makoff, J L Kennedy.   

Abstract

There is evidence for the involvement of glutamatergic transmission in the pathogenesis of major psychoses. The two most commonly used mood stabilizers (ie lithium and valproate) have been found to act via the N-methyl-D-aspartate receptor (NMDAR), suggesting a specific role of NMDAR in the pathogenesis of bipolar disorder (BP). The key subunit of the NMDAR, named NMDA-1 receptor, is coded by a gene located on chromosome 9q34.3 (GRIN1). We tested for the presence of linkage disequilibrium between the GRIN1 (1001-G/C, 1970-A/G, and 6608-G/C polymorphisms) and BP. A total of 288 DSM-IV Bipolar I, Bipolar II, or schizoaffective disorder, manic type, probands with their living parents were studied. In all, 73 triads had heterozygous parents for the 1001-G/C polymorphism, 174 for the 1970-A/G, and 48 for the 6608-G/C. These triads were suitable for the final analyses, that is, the transmission disequilibrium test (TDT) and the haplotype-TDT. For the 1001-G/C and the 6608-G/C polymorphisms, we found a preferential transmission of the G allele to the affected individuals (chi(2)=4.765, df=1, P=0.030 and chi(2)= 8.395, df=1, P=0.004, respectively). The 1001G-1970A-6608A and the 1001G-1970A-6608G haplotypes showed the strongest association with BP (global chi(2)=14.12, df=4, P=0.007). If these results are replicated there could be important implications for the involvement of the GRIN1 in the pathogenesis of BP. The role of the gene variants in predicting the response to mood stabilizers in BP should also be investigated.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12610658     DOI: 10.1038/sj.mp.4001218

Source DB:  PubMed          Journal:  Mol Psychiatry        ISSN: 1359-4184            Impact factor:   15.992


  36 in total

1.  A Neural "Tuning Curve" for Multisensory Experience and Cognitive-Perceptual Schizotypy.

Authors:  Francesca Ferri; Yuliya S Nikolova; Mauro Gianni Perrucci; Marcello Costantini; Antonio Ferretti; Valentina Gatta; Zirui Huang; Richard A E Edden; Qiang Yue; Marco D'Aurora; Etienne Sibille; Liborio Stuppia; Gian Luca Romani; Georg Northoff
Journal:  Schizophr Bull       Date:  2017-07-01       Impact factor: 9.306

2.  A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression.

Authors:  Nancy Diazgranados; Lobna Ibrahim; Nancy E Brutsche; Andrew Newberg; Phillip Kronstein; Sami Khalife; William A Kammerer; Zenaide Quezado; David A Luckenbaugh; Giacomo Salvadore; Rodrigo Machado-Vieira; Husseini K Manji; Carlos A Zarate
Journal:  Arch Gen Psychiatry       Date:  2010-08

3.  Replication of ketamine's antidepressant efficacy in bipolar depression: a randomized controlled add-on trial.

Authors:  Carlos A Zarate; Nancy E Brutsche; Lobna Ibrahim; Jose Franco-Chaves; Nancy Diazgranados; Anibal Cravchik; Jessica Selter; Craig A Marquardt; Victoria Liberty; David A Luckenbaugh
Journal:  Biol Psychiatry       Date:  2012-01-31       Impact factor: 13.382

Review 4.  Mood-stabilizers target the brain arachidonic acid cascade.

Authors:  Jagadeesh S Rao; Stanley I Rapoport
Journal:  Curr Mol Pharmacol       Date:  2009-06       Impact factor: 3.339

5.  Microarray data integration for genome-wide analysis of human tissue-selective gene expression.

Authors:  Liangjiang Wang; Anand K Srivastava; Charles E Schwartz
Journal:  BMC Genomics       Date:  2010-11-02       Impact factor: 3.969

6.  Altered expression of apoptotic factors and synaptic markers in postmortem brain from bipolar disorder patients.

Authors:  Hyung-Wook Kim; Stanley I Rapoport; Jagadeesh S Rao
Journal:  Neurobiol Dis       Date:  2009-11-26       Impact factor: 5.996

Review 7.  Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders.

Authors:  Gerard Sanacora; Carlos A Zarate; John H Krystal; Husseini K Manji
Journal:  Nat Rev Drug Discov       Date:  2008-05       Impact factor: 84.694

8.  Neural correlates of rapid antidepressant response to ketamine in bipolar disorder.

Authors:  Allison C Nugent; Nancy Diazgranados; Paul J Carlson; Lobna Ibrahim; David A Luckenbaugh; Nancy Brutsche; Peter Herscovitch; Wayne C Drevets; Carlos A Zarate
Journal:  Bipolar Disord       Date:  2013-09-18       Impact factor: 6.744

9.  Increased excitotoxicity and neuroinflammatory markers in postmortem frontal cortex from bipolar disorder patients.

Authors:  J S Rao; G J Harry; S I Rapoport; H W Kim
Journal:  Mol Psychiatry       Date:  2009-06-02       Impact factor: 15.992

Review 10.  The role of the tripartite glutamatergic synapse in the pathophysiology and therapeutics of mood disorders.

Authors:  Rodrigo Machado-Vieira; Husseini K Manji; Carlos A Zarate
Journal:  Neuroscientist       Date:  2009-05-26       Impact factor: 7.519

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.